Affinity Asset Advisors, LLC has significantly increased its stake in NextCure, Inc., now holding approximately 9.99% of the company’s common stock. This move is noteworthy as it highlights the firm’s growing confidence in NextCure and the pharmaceutical preparations sector.

The filing, submitted on November 13, 2026, reveals that Affinity Asset Advisors beneficially owns 475,626 shares of NextCure, which includes 183,666 shares that can be acquired through warrants. This strategic investment indicates a commitment to the company’s future prospects.

Company Background

Affinity Asset Advisors, LLC is a Delaware limited liability company focused on investment management. The firm primarily operates in the financial services sector, managing assets for various clients. The company has been active in filing reports with the SEC, with its recent filings including multiple Schedule 13G/A forms on the same date, November 13, 2026.

NextCure, Inc., the subject of this investment, is incorporated in Delaware and operates in the pharmaceutical preparations industry, specifically focusing on innovative therapies. The company’s principal office is located in Beltsville, Maryland.

What the Filing Says

According to the SEC filing, Affinity Asset Advisors reported that as of September 30, 2026, it holds 475,626 shares of NextCure’s common stock. The filing states, "The securities reported herein are directly held by Affinity Healthcare Fund, LP, and Affinity Asset Advisors exercises voting and investment power over these securities." This indicates that the firm is actively managing its investment in NextCure.

Impact

This increase in ownership may affect various stakeholders, including existing shareholders and potential investors in NextCure. The firm’s significant stake could signal confidence in the company’s direction and performance, potentially influencing market perceptions and investment strategies within the pharmaceutical preparations sector.

What's Next

The filing does not specify what happens next regarding Affinity Asset Advisors' investment strategy or any upcoming actions related to their stake in NextCure.